These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 31166204

  • 1. Inotropes and vasopressors use in cardiogenic shock: when, which and how much?
    Levy B, Buzon J, Kimmoun A.
    Curr Opin Crit Care; 2019 Aug; 25(4):384-390. PubMed ID: 31166204
    [Abstract] [Full Text] [Related]

  • 2. Vasopressor use in cardiogenic shock.
    Levy B, Klein T, Kimmoun A.
    Curr Opin Crit Care; 2020 Aug; 26(4):411-416. PubMed ID: 32487842
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic therapies for acute cardiogenic shock.
    Nativi-Nicolau J, Selzman CH, Fang JC, Stehlik J.
    Curr Opin Cardiol; 2014 May; 29(3):250-7. PubMed ID: 24686400
    [Abstract] [Full Text] [Related]

  • 4. Inotrope and vasopressor use in cardiogenic shock: what, when and why?
    Hu K, Mathew R.
    Curr Opin Crit Care; 2022 Aug 01; 28(4):419-425. PubMed ID: 35792520
    [Abstract] [Full Text] [Related]

  • 5. Inotropic Agents and Vasopressors in the Treatment of Cardiogenic Shock.
    Shabana A, Dholoo F, Banerjee P.
    Curr Heart Fail Rep; 2020 Dec 01; 17(6):438-448. PubMed ID: 33103204
    [Abstract] [Full Text] [Related]

  • 6. The medical treatment of cardiogenic shock: cardiovascular drugs.
    De Backer D, Arias Ortiz J, Levy B.
    Curr Opin Crit Care; 2021 Aug 01; 27(4):426-432. PubMed ID: 33797431
    [Abstract] [Full Text] [Related]

  • 7. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality.
    Tarvasmäki T, Lassus J, Varpula M, Sionis A, Sund R, Køber L, Spinar J, Parissis J, Banaszewski M, Silva Cardoso J, Carubelli V, Di Somma S, Mebazaa A, Harjola VP, CardShock study investigators.
    Crit Care; 2016 Jul 04; 20(1):208. PubMed ID: 27374027
    [Abstract] [Full Text] [Related]

  • 8. A Review of Inotropes and Inopressors for Effective Utilization in Patients With Acute Decompensated Heart Failure.
    Nandkeolyar S, Ryu R, Mohammad A, Cordero-Caban K, Abramov D, Tran H, Hauschild C, Stoletniy L, Hilliard A, Sakr A.
    J Cardiovasc Pharmacol; 2021 Sep 01; 78(3):336-345. PubMed ID: 34117179
    [Abstract] [Full Text] [Related]

  • 9. Cardiogenic shock: Inotropes and vasopressors.
    Amado J, Gago P, Santos W, Mimoso J, de Jesus I.
    Rev Port Cardiol; 2016 Dec 01; 35(12):681-695. PubMed ID: 27836218
    [Abstract] [Full Text] [Related]

  • 10. Vasopressors and Inotropes in Sepsis.
    Stratton L, Berlin DA, Arbo JE.
    Emerg Med Clin North Am; 2017 Feb 01; 35(1):75-91. PubMed ID: 27908339
    [Abstract] [Full Text] [Related]

  • 11. State of Shock: Contemporary Vasopressor and Inotrope Use in Cardiogenic Shock.
    Bloom JE, Chan W, Kaye DM, Stub D.
    J Am Heart Assoc; 2023 Aug 01; 12(15):e029787. PubMed ID: 37489740
    [Abstract] [Full Text] [Related]

  • 12. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials.
    Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pasin L, Zangrillo A, Landoni G.
    Br J Anaesth; 2015 Nov 01; 115(5):656-75. PubMed ID: 26475799
    [Abstract] [Full Text] [Related]

  • 13. Vasopressor and Inotrope Therapy in Cardiac Critical Care.
    Jentzer JC, Hollenberg SM.
    J Intensive Care Med; 2021 Aug 01; 36(8):843-856. PubMed ID: 32281470
    [Abstract] [Full Text] [Related]

  • 14. Role of medical management of cardiogenic shock in the era of mechanical circulatory support.
    Blumer V, Marbach J, Veasey T, Kanwar M.
    Curr Opin Cardiol; 2022 May 01; 37(3):250-260. PubMed ID: 35612937
    [Abstract] [Full Text] [Related]

  • 15. Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock.
    Lewis TC, Aberle C, Altshuler D, Piper GL, Papadopoulos J.
    J Cardiovasc Pharmacol Ther; 2019 Mar 01; 24(2):130-138. PubMed ID: 30175599
    [Abstract] [Full Text] [Related]

  • 16. Inotropic agents in cardiogenic shock.
    Polyzogopoulou E, Arfaras-Melainis A, Bistola V, Parissis J.
    Curr Opin Crit Care; 2020 Aug 01; 26(4):403-410. PubMed ID: 32496275
    [Abstract] [Full Text] [Related]

  • 17. [Use of vasopressors and inotropics in cardiogenic shock].
    Lemm H, Dietz S, Janusch M, Buerke M.
    Herz; 2017 Feb 01; 42(1):3-10. PubMed ID: 28101622
    [Abstract] [Full Text] [Related]

  • 18. Mortality benefit of vasopressor and inotropic agents in septic shock: a Bayesian network meta-analysis of randomized controlled trials.
    Oba Y, Lone NA.
    J Crit Care; 2014 Oct 01; 29(5):706-10. PubMed ID: 24857641
    [Abstract] [Full Text] [Related]

  • 19. Review article: inotrope and vasopressor use in the emergency department.
    Senz A, Nunnink L.
    Emerg Med Australas; 2009 Oct 01; 21(5):342-51. PubMed ID: 19694785
    [Abstract] [Full Text] [Related]

  • 20. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials.
    Belletti A, Benedetto U, Biondi-Zoccai G, Leggieri C, Silvani P, Angelini GD, Zangrillo A, Landoni G.
    J Crit Care; 2017 Feb 01; 37():91-98. PubMed ID: 27660923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.